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PENGARUH GEN POLIMORFISME ORM1, PXR, CAR, CYP3A4 DAN CYP3A5 
DALAM MEMPENGARUHI RISIKO MENDAPAT LEUKEMIA MEILOID 
KRONIK DAN TINDAK BALAS TERHADAP RAWATAN IMATINIB 
MESYLATE 
ABSTRAK 
Polimorfisme genetik telah dikenali dengan baik sebagai sumber perbezaan antara 
individu dalam risiko mendapat penyakit dan tindak balas rawatan. Asosiasi antara 
varian genetik manusia dan kecenderungan terhadap penyakit serta aktiviti rintangan 
terhadap pelbagai jenis ubat yang berinteraksi dengan beratus protein seperti reseptor, 
penggangkut dan enzim metabolisme telah diterangkan. Leukaemia mieloid kronik 
(CML) merupakan gangguan mieloproliferatif, yang mana molekulnya disasarkan oleh 
ubat imatinib mesylate (IM), iaitu ubat yang berpiawaian emas. Walaupun 
keberkesanannya sangat baik, rintangan terhadap IM telah dijumpai dalam sebilangan 
besar pesakit CML. Pembentukkan rintangan ini boleh disebabkan oleh beberapa faktor. 
Salah satu faktor yang berpotensi adalah kepelbagaian farmakokinetik yang terhasil 
daripada polimorfisme genetik dalam gen IM metabolisme. Kajian ini telah dilaksanakan 
terhadap sejumlah 540 subjek [270 pesakit CML (139 IM rintang dan 131 IM tindak 
balas baik) dan 250 individu sihat] untuk mengkaji frekuensi genotip dan polimorfisme 
ORM1 520G>A, PXR 1792A>G, CAR 540C>T, CYP3A4 878T>C dan CYP3A5 
6986A>G terhadap risiko mendapat CML dan tindak balas IM. Penjenisan gen telah 
dilakukan dengan menggunakan tiga kaedah, iaitu kaedah penjujukan DNA, kaedah 
Tindak Balas Berantai Polimorfisme-Pemotongan Panjang Cebisan (PCR-RFLP) dan 
kaedah Alel Khusus-PCR (AS-PCR). Genotip kemudiannya telah dikategorikan kepada 
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tiga, iaitu homozigot jenis liar, heterozigot dan homozigot varian. Hubungan antara 
varian alel dengan risiko kerentanan CML dan tindak balas terhadap rawatan IM telah 
dinilai dengan menggunakan nisbah kemungkinan (OR) dengan 95% selang keyakinan 
yang dikira menggunakan regresi logistik. Hasil kajian menunjukkan tiada genotip 
homozigot varian ditemui bagi CYP3A4 878T>C dan ORM1 520G>A dalam kedua-dua 
pesakit CML dan individu sihat. Apabila asosiasi antara genotip dengan risiko 
kerentanan CML dinilai, polimorfisme PXR 1792A>G dan ORM1 520G>A 
menunjukkan hubungan yang tidak signifikan terhadap risiko kerentanan CML. 
Manakala, genotip homozigot varian (TT) CAR 540C>T (OR 3.638; 95% CI: 1.779-
7.523, p<0.001) dan genotip heterozigot (TC) CYP3A4 878T>C (OR 3.387; 95% CI: 
1.433-8.007, p=0.005) menunjukkan hubungan yang signifikan terhadap risiko 
kerentanan CML. Manakala, kedua-dua genotip, heterozigot (AG) dan homozigot varian 
(GG) CYP3A5 6986A>G menunjukkan kesan perlindungan daripada kerentanan 
terhadap CML (OR 0.171; 95% CI: 0.090-0.324, p<0.001 dan OR 0.257; 95% CI: 
0.126-0.525, p<0.001, masing-masing). Seterusnya, apabila asosiasi antara genotip 
dengan tindak balas IM dalam pesakit CML dinilai, hasilnya menunjukkan bahawa SNP 
ORM1 520G>A dan CYP3A4 878T>C tidak signifikan berkaitan dengan tindak balas 
IM. Namun begitu, kedua-dua genotip, heterozigot dan homozigot varian PXR 1792A>G 
(OR 2.769; 95% CI: 1.290-5.943, p=0.007 dan OR 2.632; 95% CI: 1.030-6.723, 
p=0.041, masing-masing) dan CAR 540C>T (OR 2.700; 95% CI: 1.116-6.536, p=0.028 
dan OR 2.923; 95% CI: 1.156-7.393, p=0.023, masing-masing) menunjukkan hubungan 
yang signifikan dengan rintangan kepada IM dalam pesakit CML. Manakala, pesakit 
CML dengan genotip heterozigot (AG) dan homozigot varian (GG) CYP3A5 6986A>G 
(OR 0.171; 95% CI: 0.090-0.324, p<0.001 dan OR 0.257; 95% CI: 0.126-0.525, 
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p<0.001, masing-masing) menunjukkan hubungan yang signifikan dengan tindak balas 
yang baik terhadap IM dalam kalangan pesakit CML. Akhir sekali, apabila risiko dinilai 
berdasakan gabungan genotip, beberapa  gabungan telah dikaitkan dengan rintangan 
terhadap IM dan beberapa yang lain telah dikaitkan dengan  tindak balas yang baik 
terhadap IM. Walaupun beberapa genotip berkait dengan risiko kerentanan dan respon 
terhadap IM dalam kalangan pesakit CML telah dijumpai, kajian lanjut perlu dilakukan 
pada skala yang lebih besar bagi mengesahkan sama ada polimorfisme ini boleh 
digunakan sebagai penanda bio prediktif.  
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INFLUENCE OF ORM1, PXR, CAR, CYP3A4 AND CYP3A5 GENE 
POLYMORPHISMS IN MEDIATING SUSCEPTIBILITU RISK TO CHRONIC 
MYELOID LEUKAEMIA AND RESPONSE TO IMATINIB MESYLATE 
THERAPY 
ABSTRACT 
Genetic polymorphisms are well recognized sources of individual differences in disease 
risk and treatment response. Associations between human genetic variants and 
predisposition to diseases and adverse events for different kinds of drug interactions 
with hundreds of protein like receptors, transporters and metabolizing enzymes have 
been described. Chronic myeloid leukaemia (CML) is a myeloproliferative disorder for 
which the molecular targeted drug Imatinib mesylate (IM), is the gold standard drug. 
Despite its excellent efficacy, resistance to IM emerges in a significant number of CML 
patients. Development of resistance could be due to several factors. Pharmacokinetic 
variability as a result of genetic polymorphisms in IM metabolizing genes could be a 
potential factor. This study was undertaken in a total of 540 subjects [270 CML patients 
(139 IM resistant and 131 IM good responder) and 250 normal healthy controls] to 
investigate the genotype frequencies and the impact of ORM1 520G>A, PXR 1792A>G, 
CAR 540C>T, CYP3A4 878T>C and CYP3A5 6986A>G polymorphisms towards CML 
susceptibility risk and IM response. Genotyping was performed by using three methods, 
DNA sequencing, Polymerase Chain Reaction – Restriction Fragment Length 
Polymorphisms (PCR-RFLP) and Allele Specific – PCR (AS-PCR) technique. The 
genotypes were categorized into homozygous wild type, heterozygous and homozygous 
variant genotype. The association between allelic variants and CML susceptibility risk 
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and response to IM treatment were assessed by means of odds ratio (OR) with 95% 
confident intervals calculated by logistic regression. Results showed absence of 
homozygous variant genotype of CYP3A4 878T>C and ORM1 520G>A in both CML 
patients and normal healthy controls. When the association of genotypes with CML 
susceptibility risk was assessed, polymorphisms 520G>A of ORM1 and 1792A>G of 
PXR showed no significant associations with CML susceptibility risk. Whereas, the 
homozygous variant (TT) genotypes of CAR 540C>T (OR 3.638; 95% CI: 1.779-7.623, 
p<0.001) and the heterozygous (TC) genotype of CYP3A4 878T>C (OR 3.387; 95% CI: 
1.433-8.007, p=0.005) were significantly associated with CML susceptibility risk. In 
contrast, both heterozygous (AG) and homozygous variant (GG) genotype of CYP3A5 
6986A>G showed protective effect for susceptibility to CML (OR 0.310; 95% CI: 
0.180-0.535, p<0.001 and OR 0.140; 95% CI: 0.079-0.246, p<0.001, respectively). Next, 
when the associations of genotypes with IM response in CML patients were evaluated, 
the SNPs ORM1 520G>A and CYP3A4 878T>C were not significantly associated with 
IM response. But, both heterozygous and homozygous variant genotypes of PXR 
1792A>G (OR 2.769; 95% CI: 1.290-5.943, p=0.007 and OR 2.632; 95% CI: 1.030-
6.723, p=0.041, respectively) and CAR 540C>T (OR 2.700; 95% CI: 1.116-6.536, 
p=0.028 and OR 2.923; 95% CI: 1.156-7.393, p=0.023, respectively) showed significant 
association with IM resistance in CML patients. However, CML patients with 
heterozygous (AG) and homozygous variant (GG) genotypes of CYP3A5 6986A>G (OR 
0.171; 95% CI: 0.090-0.324, p<0.001 and OR 0.257; 95% CI: 0.126-0.525, p<0.001, 
respectively) showed significant association with IM good response to IM. Finally, when 
the risk was evaluated based on the combination of genotypes, a few combinations were 
associated with IM good response and a few others with IM resistance. Although a few 
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genotypes associated with susceptibility risk and IM response in CML patients were 
observed, further studies are warranted on a larger scale to validate whether these 
polymorphisms could be used as predictive biomarkers.  
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CHAPTER 1 
 
 
 
INTRODUCTION 
 
 
 
1.1 Overview of cancer 
Cancer is the leading cause of death worldwide, after heart disease. The incidence of 
cancer has been reported to be increased from 12.7 million in 2008 to 14.1 million in 
2012, and this trend is predictable to continue, with the number of new cases expected to 
rise a further 75% (Stewart and Wild, 2014). Results from GLOBOCAN  show that in 
2012 there were an estimated 14.1 million new cases of cancer diagnosed worldwide and 
8.2 million estimated deaths from cancer (Organization, 2014). About half of the cancer 
incidence burden occurs in Asia. According to the Malaysian National Cancer Registry 
report, a total of 18,219 new cancer cases were diagnosed in 2007 which comprised 
8,123 (44.6%) males and 10,096 (55.4%) females. The ten leading cancers among 
population of Malaysia in 2007 were breast, colorectal, lung, nasopharynx, cervix, 
lymphoma, leukaemia, ovary, stomach and liver (Zainal Ariffin and Nor Saleha, 2011).  
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1.1.1 Cancer development 
Cancer is the general name for a group of more than 100 diseases, all characterized by 
uncontrolled division and proliferation of abnormal cells. Mostly, cancer arises when 
there is a change in or a damage to genes, which is called a gene mutation. Mutation can 
affect the structure of the gene and stop it from working properly. Basically, gene 
mutation can occur by chance (sporadic) or be inherited. Mutations are of two types – 
somatic mutations and hereditary/germline mutations. Somatic mutations result in 
sporadic cancers. Most of the cancers are sporadic. They occur because of genetic 
changes in the cells that happen mostly by chance and build up throughout a person’s 
lifetime. They can also be caused by something that damages the cell’s DNA, such as 
carcinogenic agents. Sometimes, cancer causing gene mutation can be inherited from a 
parent. Inherited mutations are called germline mutations because they are present in 
parent’s reproductive cells, either the father’s sperm cell or the mother’s egg cell. 
Germline mutations can be passed from generation to generation. Germline mutations 
result in hereditary cancer syndromes. Typical examples of germline mutations are 
BRCA1/BRCA2 genes resulting in hereditary breast/ovarian cancer (HBOC) syndrome, 
mismatch repair (MMR) genes in Lynch syndrome etc. 
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1.1.2 General classification of cancer 
Generally, cancers are classified into two ways: by the type of tissue in which the cancer 
originates (histological type) and the location in the body where the cancer first develops 
(primary site). From a histological standpoint, cancers are grouped into six major 
categories, which are carcinoma, sarcoma, myeloma, leukaemia, lymphoma and mixed 
types. 
 
Carcinoma is a malignant neoplasm of epithelial origin or cancer of the internal 
or external lining of the body. Carcinomas comprise 80 to 90 percent of all cancer cases. 
Carcinoma is divided into two major subtypes which are adenocarcinoma and squamous 
cell carcinoma. Adenocarcinoma develops in organ or gland whereas squamous cell 
carcinoma originates in the squamous epithelium. 
 
Sarcoma refers to cancer that originates in supportive and connective tissues such 
as bones, tendons, cartilage, muscle and fat. Most common sarcoma often develops as a 
painful mass on the bone. Hence, more often than not, this occurs in young adults. 
Sarcoma tumours usually resemble the tissue in which they arise. 
 
Myeloma is the type of cancer that begins in plasma cells, a type of white blood 
cell which is made in the bone marrow. Myeloma is also known as multiple myeloma. 
Normally, plasma cells produce some of the proteins found in the blood. Plasma cells 
are responsible for producing antibodies (immunoglobulins) which are functioning for 
maintaining the body’s immune system. Mutations in plasma cells result in abnormal 
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plasma cells which multiply uncontrollably and produce only one type of antibody 
known as paraprotein which has no useful function. 
 
Leukaemia is a type of cancer that affects the blood and bone marrow. 
Leukaemia causes overproduction of immature white blood cells. These immature white 
blood cells do not function normally as they should. Therefore, the patient is often prone 
to infection. Leukaemia also affects red blood cells and cause poor blood clotting and 
fatigue due to anaemia.  
 
Lymphoma is a type of cancer that develops in the lymphatic system which 
affects the immune system. Generally there are two main types of lymphoma which are 
Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). 
 
Cancer also can be formed in mixed type. The type of components may be within 
one category or from different categories. Examples of this cancer types are 
adenosquamous carcinoma, mixed mesodermal tumour, carcinoma and teratocarcinoma. 
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Figure 1.1 Ten most frequent cancers in Malaysia 2007, (adapted from Zainal 
Ariffin and Nor Saleha, 2011)  
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1.2 Leukaemia 
Leukaemia is a group of neoplastic disorders that arise in haematopoietic stem cells. 
Leukaemia is characterized by the uncontrolled proliferation and accumulation of 
immature blood cells in the bone marrow and peripheral blood (Osaro Erhabor and 
Adias, 2013). Once the disease starts, leukaemia cells begin accumulating in the bone 
marrow replacing or crowding out normal white and red blood cells and also 
megakaryocyte. When healthy bone marrow gets replaced by these immature cells, it 
causes the number of normal red and white blood cells and platelets to be decreased. The 
most common manifestations of leukaemia include anaemia, neutropenia, 
thrombocytopenia, weakness and an increase in infections (Osaro Erhabor and Adias, 
2013). 
 
 In year 2007, leukaemia had been reported to rank as number 7 out of 10 most 
common cancers in the Malaysian population, with 4.1% (Zainal Ariffin and Nor Saleha, 
2011). In Malaysia, there were 741 cases of leukaemia diagnosed in 2007 and registered 
at NCR, and comprised 419 (56.5%) males and 322 females (43.5%) with the incidence 
rate as 3.5 per 100 000 and 2.7 per 100 000, respectively. Among male leukaemia 
patients, Malay male showed higher preponderance (241), followed by Chinese (103) 
and Indian (29) ethnic groups. Among female leukaemia patients also, Malay female 
ranked number one which was 184, followed by Chinese (63) and Indian (28) ethnic 
groups. It seems that Malay ethnic groups are more prone to develop leukaemia, than 
Chinese and Indian ethnics (Zainal Ariffin and Nor Saleha, 2011). 
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1.2.1 Classification of Leukaemia 
Leukaemia can present in myeloid or lymphoid and acute or chronic forms. If the 
leukaemia is myeloid in origin, it will involve the myeloid tissue mainly (bone marrow), 
whereas if the leukaemia started in the lymphoid tissue, it will involve both the lymph 
nodes and the bone marrow lymphoid tissue. Acute leukaemia can be described as when 
the malignant cells are immature blasts with a rapid cell proliferation rate. In contrast, 
leukaemia is described as chronic when the malignant cells are more mature than those 
of acute leukaemias. Chronic leukaemias have a less devastating clinical course than do 
acute leukaemias (Al-Tubaikh, 2010). 
 
There are four major types of leukaemia, Acute Lymphoblastic Leukaemia 
(ALL), Chronic Lymphocytic Leukaemia (CLL), Acute Myeloid Leukaemia (AML) and 
Chronic Myeloid Leukaemia (CML).  
 
Acute lymphoblastic leukaemia (ALL) also known as acute lymphocytic 
leukaemia, is a malignant disease of the bone marrow in which early lymphoid 
precursors proliferate and replace the normal haematopoietic cells of the marrow (Seiter 
et al., 2014). ALL is characterized by excess lymphoblasts in the bone marrow. It 
progresses rapidly, replacing healthy cells that produce functional lymphocytes with 
leukaemia cells that cannot mature properly. ALL is the most common type of 
leukaemia affecting children.  
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Chronic lymphocytic leukaemia (CLL) is a lymphoproliferative disorder, 
composed by monomorphic round B immature lymphocytes involving peripheral blood, 
bone marrow and lymphoid organs (Swerdllow et al., 2008). Since CLL is a chronic 
type, it develops slowly. CLL develops when too many abnormal lymphocytes grow, 
crowding out normal blood cells and making it difficult for the body to fight infection. 
In CLL, the abnormal lymphocytes take longer time to develop and multiply in the bone 
marrow. CLL is one of the most common leukaemias among the adults (Scarfò et al., 
2016).  
 
Acute Myeloid Leukaemia (AML) is a clonal haematopoietic disorder resulting 
from genetic alterations in normal haematopoietic stem cells. These alterations disrupt 
normal differentiation, leading to excessive proliferation of abnormal immature 
leukemic cells known as blasts (Kumar, 2011). AML is the most common type of acute 
leukaemia affecting adults. AML is characterized by the rapid growth of abnormal white 
blood cells that accumulate in the bone marrow and interfere with the production of 
normal cells (Chaudhary and Chaudhary, 2011). Because AML is an acute type of 
leukaemia, it can spread quickly to the blood and other parts of the body, such as lymph 
nodes, liver, spleen, brain and spinal cord, and testicles if not quickly treated (Society, 
2014). It also can be fatal. 
 
The fourth type of common leukaemia is chronic myeloid leukaemia (CML). 
This study is focused on Chronic Myeloid Leukaemia. 
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1.3 Chronic Myeloid Leukaemia (CML) 
Chronic Myeloid Leukaemia (CML) is a haematopoietic stem cell disorder characterized 
by excessive proliferation of leucocytes of myeloid series in the bone marrow and 
circulating blood (Hoyle et al., 2011). CML normally comprises 3 clinically recognized 
phases. Approximately 90% of patients are diagnosed during the typically indolent 
chronic phase (CP), which is followed by an accelerated phase (AP) and a terminal 
blastic phase (BP). In CML, the bone marrow produces too many white cells, called 
granulocytes. These cells, gradually crowd the bone marrow, interfering with normal 
blood cell production. They also spill out of the bone marrow and circulate around the 
body in the bloodstream. Over time, a shortage of red cells and platelets can cause 
anaemia, bleeding and/or bruising. Most cases of CML occur in adults and comprises 
15%-20% of all adult leukaemias, with a median age of diagnosis of 50 years (Rumjanek 
et al., 2013). Rarely CML occurs in children too. Among childhood leukaemias, CML is 
a rare entity with an annual incidence of one case per million children (Nikumbh et al., 
2012).  
 
CML is characterized by the Philadelphia (Ph) chromosome, created by a 
reciprocal translocation between chromosomes 9 and 22 t(9:22)(q34;q11 (Al-Achkar et 
al., 2013). This translocation initially occurs in a cell in the bone marrow. This abnormal 
cell divides further and produces a clone of abnormal cells which results in development 
of CML. Figure 1.2 shows the formation of Philadelphia chromosome. Philadelphia 
translocation t(9;22)(q34;q11) is detected in 95% of chronic myeloid leukaemia (CML) 
cases (Zheng et al., 2009). This reciprocal t(9:22) translocation, transfers the Abelson 
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(ABL) proto-oncogene on chromosome 9 to the breakpoint cluster region (BCR) of 
chromosome 22, resulting in the formation of a BCR/ABL fusion gene  (Al-Achkar et 
al., 2013), which function as an oncogene. BCR/ABL fusion gene encodes for a 210 
kDa protein with increased tyrosine kinase activity. 
 
ABL and BCR are normal cellular genes on chromosomes 9 and 22, respectively. 
The ABL gene encodes a tyrosine kinase enzyme whose activity is tightly regulated 
(controlled). In the formation of the Ph chromosome, two fusion genes are generated: 
BCR/ABL on the Ph chromosome 22 and ABL-BCR on the chromosome 9 participating 
in the translocation. The BCR/ABL fusion gene encodes a 210 kDa protein with 
deregulated (uncontrolled) tyrosine kinase activity. The presence of this protein in the 
CML cells is strong evidence of its pathogenic (disease-causing) role.  
 
 A tyrosine kinase plays an important role in communicating signals within a cell 
(signal transduction) and regulating cellular activity, such as cell proliferation, 
differentiation, migration, metabolism and programmed cell death. The protein kinase 
can be mutated and causing transformation of its functions due to mutations, 
overexpression and autocrine paracrine stimulation leading to malignancy (Paul and 
Mukhopadhyay, 2004). Activation of BCR/ABL gene promotes phosphorylation of a 
chimeric protein, which is responsible for the proliferation of a clone of malignant 
myeloid cells in the bone marrow due to excessive tyrosine kinase activity. This 
activation is responsible for CML pathogenesis (Danier et al., 2011).  
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Figure 1.2  The formation of Philadelphia chromosomes as a result of reciprocal 
translocation between chromosome 9 and chromosome 22 (Adapted from website 
National Institute of Health, National Cancer Institutes) 
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1.3.1 Staging of Chronic Myeloid Leukaemia 
Chronic myeloid leukaemias have three clinical phases, chronic phase (CP), accelerated 
phase (AP) and blast phase (BP). The CP, AP and BP are defined according to European 
LeukaemiaNet (ELN) (Baccarani et al., 2009; Baccarani et al., 2013; Baccarani et al., 
2006) and by the World Health Organisation (WHO) (Swerdllow et al., 2008) 
recommendations.  Approximately 90% of patients with CML are in the chronic phase at 
the time of diagnosis. Patients in CP usually are asymptomatic or show only mild 
symptoms. Without adequate and effective treatment, patients in this phase can 
potentially progress to an accelerated phase. 
  
 According to European LeukaemiaNet (ELN), CML patients are considered to be 
in the accelerated phase when they have following criteria: blasts in blood or marrow 
contains 15-29%, or blasts plus promelocytes in blood or bone marrow >30%, with 
blasts <30%, basophils in blood ≥20%, persistent thrombocytopenia (<100 x 109/L) 
unrelated to therapy and having clonal chromosome abnormalities in Ph+ cells 
(CCA/Ph+), major route, on treatment. According to World Health Organisation 
(WHO), accelerated phase of CML is defined as presence of 10-19% blasts in blood or 
bone marrow, ≥20% basophils in blood, persistent thrombocytopenia (<100 x 109/L) 
unrelated to therapy, CCA/Ph+ on treatment, thrombocytosis (>1000 x 10
9
/L) 
unresponsive to therapy, and increasing spleen size and increasing white blood cell 
count unresponsive to therapy. The accelerated phase is often a sign that the disease is 
progressing and transforming to blast crisis and that the current treatment is ineffective. 
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 Blast phase is the final phase in the progression of CML. Blast phase is 
characterized by the presence of rapid disease progression and shorter cell survival. 
According to ELN, a CML patient is said to be in the blast phase if he/she present the 
following criteria during his/her active treatment: ≥30% blast in the blood or bone 
marrow, and extramedullary blast proliferation, apart from spleen. Based on WHO, a 
CML patient is defined to be in the blast phase when he/she has the following criteria: 
presence of ≥20% blasts in blood or bone marrow, presence of large foci or clusters of 
blasts in the bone marrow biopsy and extramedullary blast proliferation, apart from 
spleen. 
 
1.4 Problem statement 
The most exciting breakthrough in the development of CML has been the development 
of Imatinib mesylate (IM) as an orally bioavailable therapeutic agent. IM, also known as 
Glivec/Gleevec, is a molecularly targeted drug developed against BCR/ABL fusion 
product and has been approved and successfully introduced in the treatment of CML. 
Gleevec was approved by the Food and Drug Administration (FDA), United States of 
America since 2001 (Paula, 2012). 
 
Despite the clinical success, with IM demonstrating long-term survival for the 
majority of patients, a significant proportion of patients (30-40%) show suboptimal 
response to IM or develop resistance to IM. Development of resistance to IM could be 
due to a heterogeneous array of mechanisms. There are two broad mechanisms that are 
associated with development of resistance to IM in CML patients. These two 
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mechanisms are 1) those involving BCR/ABL dependent pathway and 2) those 
involving BCR/ABL independent pathways. BCR-ABL dependent mechanism generally 
includes point mutations within the BCR/ABL kinase domain that interfere with 
imatinib binding and also the over-expression or amplification of the BCR/ABL gene. 
An earlier study from HGC had shown that IM resistance through BCR/ABL dependent 
mechanism (BCR/ABL mutation and BCR/ABL amplification) occur in only 
approximately 30% of CML patients showing resistance to IM. This showed that the 
mechanism of IM resistance among the rest of CML patients might be due to BCR/ABL 
independent mechanisms. Among BCR/ABL independent mechanisms, a number of 
factors may influence the plasma and tissue levels of IM and under certain 
circumstances, may contribute to pharmacologic resistance. 
 
The mechanisms that may affect IM sensitivity include drug dependent 
mechanisms due to modification of drug disposition resulting in altered expression of 
the proteins. There are three main systems that are involved in the intracellular drug 
levels, (1) the drug influx system of the solute carrier family (SLC), (2) the drug efflux 
system of ATP binding cassette transporters (ABC transporter, also called MDR 
multidrug resistance transporter) and (3) the xenobiotic (drug) metabolizing enzymes 
(XME). Drug uptake and efflux transporters are likely to be involved in IM absorption, 
distribution and excretion, thereby influencing pharmacokinetics. The efficacy and 
toxicity of IM seem to depend on both IM pharmacokinetics, influenced by several 
enzymes and transporters, and IM pharmacodynamics, influenced by the mutational 
studies of the target. Recently, attention is focused on inter-patient pharmacokinetic 
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variability. Pharmacokinetic differences between patients might be due to the patient’s 
genetics. 
 
Genetic polymorphisms in key genes encoding transporters, metabolizing and 
binding enzymes of IM may influence the intracellular IM delivery and therefore, on the 
effectiveness of the drugs. Genetic polymorphisms of candidate genes could affect 
expression of corresponding proteins and thus may bring about differences in response 
to IM. Given that genetic differences between individuals or population can impact the 
efficacy of drugs, defining pharmacogenetic differences among patients is regarded 
as an important aspect which needs to be addressed in understanding the 
development of resistance to IM in CML patients.  
 
What are the factor(s) that cause the development of CML? It is still largely 
unknown. A few risk factors have been identified such as exposure to radiation or 
radiation therapy. Previous chemotherapy for other types of cancer has also been 
associated with development of CML. Long term exposure to high levels of certain 
environmental carcinogens (chemicals such as benzene 1-3 butadiene, dioxin, metals) 
are the other risk factors for CML development. Benzene which is used in massive 
amounts in large number of industries such as agricultural industry, petroleum industry, 
is a known carcinogen. However, not all individuals exposed to these risk factors do 
develop CML and individuals who are never exposed to these risk factors also develop 
CML. So also, a few earlier studies (Biernaux et al., 1995; Bose et al., 1998) had 
demonstrated the presence of very low levels of BCR/ABL fusion gene in the blood of 
healthy people, but who never developed CML. All the above facts reiterates that, in 
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addition to Ph chromosome translocation, other predisposing risk factors are also 
necessary for development of CML. This indicates the importance of undertaking 
studies to identify host genetic susceptibility factors for the development of CML. 
 
1.5 Significance of the present study 
Resistance to IM could be directly or indirectly caused by pharmacokinetic factors such 
as an increase in cellular efflux, a decrease in cellular influx of IM, intrinsic variations in 
the metabolism of IM, incomplete adherence of IM etc. Pharmacogenetics is concerned 
with understanding individual genetic variability and how it affects response to 
treatment. It seems clear that the effect of IM depends on several genes. An approach 
involving multiple candidate genes is clearly needed to elucidate the real impact of 
candidate gene polymorphisms on IM response. 
 
The xenobiotic metabolizing and transporter enzymes play important roles in the 
process of drug disposition and detoxification of numerous foreign and endogenous 
chemicals. Polymorphisms in genes coding for metabolizing enzymes and drug 
transporters can affect drug efficacy and toxicity. Thus, such genetic variations can 
influence pharmacokinetic and pharmacodynamic parameters of anticancer drugs 
(Bosch, 2008). Other than that, interindividual genetic variations also cause different 
individuals to respond differently to the same dosage of a drug (Bosch, 2008; Dasgupta 
and Wahed, 2014).  
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The detoxification processes occurring in both tumour and healthy cells include 
oxidation/reduction reactions by phase I enzymes such as cytochrome P450 (CYP)-
related enzymes. Enhanced activity of phase I enzymes may result in the inactivation of 
drug and enhanced chemoresistance. On the other hand, several anticancer agents are 
administered as inactive pro-drugs and hence require metabolic activation by phase I 
proteins. Accordingly, reduced sensitivity to these drugs may be due to the reduced 
expression or function of the enzymes. Altogether, alterations in drug metabolism that 
are due either to an enhanced production of inactive metabolites or a reduced activation 
of pro-drugs may decrease the intracellular concentrations of the active agent, reducing 
the efficacy of chemotherapy  (Marin et al. 2010). Changes in the expression or function 
of these enzymes that are due to genetic variations especially single nucleotide 
polymorphisms, in these genes involved in drug biotransformation in cancer cells, may 
dramatically alter the final success of pharmacological treatment (Yu et al. 2012). 
 
 CYP belongs to a large group of more than 60 enzymes that are responsible for 
the activation or inactivation of most clinically important drugs including cancer 
chemotherapeutic drugs such as IM. CYP enzymes can play important roles in reducing 
the intracellular concentration of drugs and in affecting cancer drug resistance. The 
expression of drug metabolizing enzymes can therefore either potentiate or reduce the 
toxicity of chemicals and drugs. Variations in both the activation and inactivation 
pathways are important variables that can lead to drug resistance. The CYP genes are 
highly polymorphic and certain genetic variants have been demonstrated to be clinically 
relevant. IM is a potent mechanism-based inhibitor of CYP3A4 and CYP3A5 enzymes. 
The SNPs CYP3A4*18 and CYP3A5*3 exhibit inter individual differences in their 
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mRNA expression levels. So it was aimed to investigate the genotype frequencies of 
SNPs CYP3A4*18 and CYP3A5*3 in CML patients undergoing IM therapy and 
determine their association with IM response. 
 
 Most of the early works had focused on drug metabolizing enzyme genes 
because of their direct involvement in conversion of drugs and their removal from the 
body. The expression of many XMEs and transporters is up-regulated by a group of 
ligand-activated transcription factors namely nuclear receptors (NRs) in order to 
accommodate chemical challenges. The synergy and co-operation of the three systems is 
the result of co-ordinated regulation of the expression of these systems by nuclear 
receptors. The mammalian NR superfamily of transcription factors such as Pregnane X 
receptor (PXR, NR1I2) and Constitutive Androstane receptor (CAR, NR1I3) are 
involved in xenobiotic regulation of gene expression at the transcriptional level (Tolson 
and Wang, 2010). Mutations in either one of the NR will affect the functions of NR as 
well as cause failure or reduce efficacy in the XME and transporters. However, in order 
to gain a better understanding, variations in the nuclear receptors that affect the 
regulation of DMEs are also necessary. Nuclear receptors (a superfamily of transcription 
factors) especially Pregnane X Receptor (PXR) and Constitutive Androstane Receptor 
(CAR) play major role in detoxification process by controlling a network of signaling 
pathways that regulate the expression of specific batteries of genes involved in the 
detoxification machinery (Germain et al., 2006). Because they interfere with other 
signaling pathways, chronic activation of these NRs could alter disease promotion. Some 
aspects of drug metabolism and transport are regulated by PXR and CAR genes (Evans, 
2005).  
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According to their role as master xenobiotic responsive receptors, CAR and PXR 
might contribute to the well known intra and inter-subject variability in anticancer drug 
response. Genetic factors affecting CAR or PXR (expression or activation levels) may 
affect the cytotoxic threshold of tumour cells to chemotherapy which can consequently 
mask or attenuate pharmacogenetic associations. Recently, PXR pathway has also been 
implicated in drug resistance via the upregulation of drug metabolizing genes such as 
CYP3A4 and CYP3A5 (Basseville et al., 2011). Genetic variation in NRs will affect the 
functions of NRs as well as cause failure or reduced efficacy in regulating the XMEs and 
transporters which in turn affect treatment response. So this study aimed to investigate 
the frequencies of SNPs 1792A>G of PXR and SNP 540C>T of CAR in CML patients 
on IM therapy and determine the association with IM response.  
 
Orosomucoid (ORM), also known as α-1 Acid Glycoprotein (AGP), is a 
circulating serum protein that has been proposed as a factor that reduces drug efficacy 
through nonspecific binding to the drug. Following absorption, IM bind to plasma 
protein such as albumin and α-1 acid glycoprotein (AGP) and distribute from the 
intravascular spaces to their targets in their extra vascular space. Only unbound (free) 
drugs are pharmacologically active. So, plasma AGP concentration has a marked 
influence on total IM concentration. Previous mouse models had implicated a possible 
role for IM sequestration in the plasma by the serum α-1 acid glycoprotein, as a 
mechanism of therapy resistance. Individual differences in AGP binding may explain 
some of the inter-patient variability in the observed total plasma exposure to IM. 
Elevated levels of AGP had been observed in patients with CML and with further 
increased levels in patients with disease progression (Gambacorti-Passerini et al., 2003). 
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It is presumed that modulation of IM binding to α-1 acid glycoprotein (AGP) in plasma 
may contribute to IM response (Rochal et al. 2008). Difference in IM binding to AGP 
protein could be due to single nucleotide polymorphisms in the AGP gene. So, it was 
planned to analyse the impact of SNP of AGP, namely 520G>A on IM response. 
 
 Although BCR/ABL fusion gene formed as a result of Philadelphia chromosome 
translocation t(9;22)(q34;q11) is essential for the development of CML, other putative 
inherited factors also are associated with the risk of development of CML. Inherited 
genetic susceptibility factors accounting for CML include genes involved in the 
activation and/or detoxification of xenobiotics including carcinogens and repair of DNA 
damage (Irigaray et al., 2007). Individual variations in metabolism of carcinogens 
account for the differences in susceptibility to cancer and could be an attributable risk 
factor. It is possible that CML develops as a result of exposure to risk factors in 
genetically susceptible individuals. How to identify individuals who have higher 
susceptibility risk for CML? Being metabolizing genes and their transcription regulators, 
do SNPs in these genes have any role in modulating susceptibility risk of Malaysian 
CML patients?  No information is available. This was another research question 
addressed in this study. So this study aimed to address this issue also.  
 
 The frequencies of the above mentioned SNPs vary across normal populations 
worldwide due to genetic heterogeneity. What are the frequencies of the SNPs 520G>A 
of ORM1, 878T>C of CYP3A4, 6986A>G of CYP3A5, 1792A>G of PXR and 540C>T 
of CAR in Malaysian population? No data is available. Genetic characterization of these 
SNPs in Malaysian population needs to be built up. So this study aimed to investigate 
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the genotype frequencies of variants of all the above SNPs in normal healthy controls 
belonging to three predominant ethnic groups (Malay, Chinese, and Indians) in 
Malaysian population.  
 
1.6 Hypothesis  
Single nucleotide polymorphisms in ORM1 (520G>A), PXR (1792 A>G), CAR 
(540C>T), CYP3A4*18 (878T>C) and CYP3A5*3 (6986 A>G) genes have potential 
influence on susceptibility risk and response to IM, either good response or resistance, in 
Chronic Myeloid Leukaemia patients. 
 
1.7 Objectives of the study 
Broad objective: 
The main objective of this study was to investigate the genotype frequencies of selected 
genetic polymorphisms of ORM1, PXR (NR1I2), CAR (NR1I3), CYP3A4 and CYP3A5 
genes in normal controls and chronic myeloid leukaemia patients in Malaysian 
population and to elucidate the association of the variant genotypes with CML 
susceptibility risk and with clinical response to Imatinib Mesylate (IM) in Chronic 
Myeloid Leukaemia patients.  
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The specific objectives of this study are: 
 
i. To investigate the genotype frequencies of SNP 520G>A of ORM1, 
1792A>G of PXR, 540C>T of CAR, 878T>C of CYP3A4 and 6986 A>G 
of CYP3A5 genes in normal healthy controls belonging to 3 ethnic groups 
(Malays, Chinese and Indian) in Malaysian population. 
 
ii. To investigate the genotype frequencies of SNP 520G>A of ORM1, 
1792A>G of PXR, 540C>T of CAR, 878T>C of CYP3A4 and 6986 A>G 
of CYP3A5 in CML patients undergoing IM therapy (both IM good 
response and IM resistant CML patients). 
 
iii. To determine the association of the above SNPs in modulating CML 
susceptibility risk. 
 
iv. To determine the association of any of these gene polymorphisms, either 
in single or in combination, with good response as well as resistance to 
IM in CML patients. 
 
v. To assess whether genotyping for these gene polymorphisms could be 
utilized as a potential pharmacogenetic tool in the future for early 
identification of good or poor responders to IM among CML patients. 
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CHAPTER 2 
 
 
 
LITREATURE REVIEW 
 
 
 
2.1  Imatinib Mesylate 
Imatinib mesylate (IM) is a first generation tyrosine kinase inhibitor that was approved 
for the frontline therapy in chronic myeloid leukaemia (CML) patients by the Food and 
Drug Administration (FDA) in 2001. Imatinib mesylate is also known as Glivec or 
Gleevec.  It is the first molecularly targeted drug developed for treatment of CML. IM is 
also used in treatment of gastrointestinal stromal tumours (GISTs). In CML, IM is 
specifically designed to inhibit the breakpoint cluster region (BCR)-Abelson (ABL) 
fusion protein. BCR/ABL fusion protein results from the chromosomal abnormality 
known as Philadelphia chromosome translocation t(9;22)(q34;q11). Imatinib has become 
first-line treatment in newly diagnosed patients with Philadelphia chromosome positive 
(Ph+) chronic phase CML, Ph+ accelerated phase or blast-crisis CML, and in patients 
with Ph+ chronic phase who have failed to respond to interferon-α therapy. Imatinib is 
well absorbed after oral administration with a biovailability exceeding 90% (Petain et 
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al., 2008). Since its approval in 2001, for frontline management of CML, IM has proven 
to be very effective in achieving high remission rates and improving prognosis. 
 
 Imatinib inhibits the BCR/ABL tyrosine kinase by competitive binding at the 
adenosine triphosphate (ATP)-binding pocket of the ABL kinase domain which prevents 
a change in conformation of the protein that would otherwise convert the molecule to its 
active form, and IM binding thereby leads to the apoptosis of target cells (Dulucq and 
Krajinovic, 2010). Figure 2.1 shows the mechanism of action of imatinib. In the absence 
of imatnib, ATP binds to BCR/ABL tyrosine kinase and transfer phosphate (PO4) from 
ATP to tyrosine residues on various substrates. This causes excess proliferation of 
myeloid cells, which is characteristic of CML. In the presence of imatinib, imatinib 
blocks the binding of ATP to the BCR/ABL tyrosine kinase, inhibiting the activity. In 
the absence of tyrosine kinase activity, substrates required for BCR/ABL function 
cannot be phosphorylated, and subsequent cellular events are abrogated (O'Dwyer et al., 
2003). 
  
 
 
 
 
 
 
 
 
